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RESEARCH ARTICLE
ALS longitudinal studies with frequent data collection at home:
study design and baseline data
SEWARD B. RUTKOVE1, KRISTIN QI1, KERISA SHELTON2, JULIE LISS4, VISAR
BERISHA3 AND JEREMY M. SHEFNER2
1Department of Neurology, Beth Israel Deaconess Medical Center, Boston, MA, USA, 2Department of Neurology,
Barrow Neurological Institute, Phoenix, AZ, USA, 3University of Arizona College of Medicine, Phoenix, AZ,
USA, 4Department of Speech and Hearing Science, Arizona State University, Phoenix, AZ, USA
Abstract
Objective: To design an ALS clinical study in which patients are remotely recruited, screened, enrolled and then assessed
via daily data collection at home by themselves or caregivers. Methods: This observational, natural-history study included
two academic medical centers, one providing overall clinical management and the other overseeing computing and web-
services design and management. Both healthy and ALS subjects were recruited on the Internet via advertisement on
governmental and foundation websites as well as through Facebook and Google paid advertisements. Individuals under-
went screening and enrollment remotely, including signing an electronic informed consent form. Participants were then
provided self-measurement equipment and instructed on their use through a series of web-based videos. The equipment
included a handgrip dynamometer, spirometer with smartphone connection, electrical impedance myography device, and
an activity tracker. ALS Functional Rating Scale-Revised data were also collected. Subjects were asked to collect data
daily for three months and twice-weekly for the subsequent six months. Results: One hundred and eleven ALS patients
and 30 healthy individuals enrolled in the study from across 41 states (74 men, 62 women). Baseline median ALSFRS-
R score was 33. Seventy two percent of the ALS patients sent equipment and 88% of the healthy subjects sent equip-
ment were able to complete a first set of measurements. Expected baseline differences between the ALS patients and
healthy participants were identified for all measures. Conclusions: It is possible to design and institute an at-home based
study in ALS patients, using a number of state-of-the-art approaches, including web-based consenting and training and
Internet-connected measurement devices.
KEYWORDS: ALS, clinical trial design, biomarkers, self-assessment
ClinicalTrials.gov Identifier: NCT03016897
Introduction
Over the past several decades, a standard approach
to clinical trial design in ALS has emerged (1). In
general, patients are screened, enrolled, and
studied at a large medical center. A variety of out-
come measures or biomarkers are obtained at
baseline, the patient is provided active drug or pla-
cebo, and then followed over a period of several
months to a year. Patient visits to the center occur
at bi- or tri-monthly intervals during which out-
comes data are gathered as well as safety and
adverse event information. At the conclusion of
the study, data are analyzed by assessing the rate
of change in a given parameter over time, with the
goal of determining whether individuals on active
treatment show a relative slowing of progression as
compared to those on placebo.
A variety of outcome measures have been
incorporated into this approach, each of which has
some intrinsic variability. These measures have
also confirmed that ALS patients progress at very
different rates, some declining slowly and others
very rapidly. These two factors together mean that
late stage trials usually require hundreds of
patients per group, studied for six months or
more, to have sufficient power to identify a treat-
ment effect. Novel trial designs have concentrated
on altering inclusion criteria to enroll a cohort of
similarly declining patients. This approach has led
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to the approval of edaravone in 2017 (2); however,
drastic limits on inclusion criteria raise questions
about the generalizability of results, and rate of
patient accrual is drastically reduced.
In addition to this limitation, the standard clin-
ical trial approach also requires that patients return
to a study center for evaluation on a frequent sched-
ule. This limits potential trial participants to those in
proximity to such a center. In addition, while travel
early in the disease may be easy, with progression, it
often becomes difficult for the patient to travel any
distance for evaluation. This can put considerable
burden on patients and their caregivers and is likely
one reason many may discontinue participation at
some point during a study (3).
An alternative strategy to help reduce study size
requirements and increase convenience would be to
have patients obtain quantitative, functional data on
themselves at home on a very frequent (e.g., daily)
basis (4). By frequent sampling, both variability of
measurement and small physiological changes in
function would both be eliminated, potentially
reducing the variability of the slope of a given meas-
ure. Such a measurement strategy should improve
the certainty in the estimation of the rate of decline
in a given person over time (see Figure 1) and thus
have the power to reduce to sample size require-
ments overall. Moreover, such measurements would
obviate the need for repeated travel to a distant
medical center. Theoretically, essentially all aspects
of a clinical trial could be performed remotely,
including dispensing drug, collection of blood sam-
ples and assessment of adverse events.
In order to better understand the potential of
this approach, we designed a study, funded by
ALS-Finding-A-Cure, entitled “ALS AT HOME,”
specifically focused on assessing possible sample-
size improvements, identifying the optimal sampling
frequency, and assessing patient acceptance of such
an approach. We employed a battery of frequently
used outcome measures that were well suited to in-
home assessments, as well as several novel end-
points. In this report, we provide an overview of the
methods developed, including enrollment and con-
senting procedures, the set-up of data collection
and web design, baseline data, and provide detailed
information on the challenges, both expected and
unexpected, with such an approach.
Methods
Overall structure (Figure 2)
Study coordination was carried out at Barrow
Neurological Institute (BNI), Phoenix, AZ; the
BNI coordination center was also responsible for all
clinical aspects of the study, including providing
institutional review board oversight, implementing
recruitment strategies, enrollment, and conducting
all subsequent participant contact, including ship-
ping of study tools and troubleshooting problems as
they arose. Beth Israel Deaconess Medical Center,
Boston, MA was responsible for all informational
technology development and oversight, including
design and implementation of the ALS AT HOME
web portal, linking the various collection tools with
data storage in the REDCap server, and automating
the sending of reminders if individuals neglected to
collect data on a given day. Weekly to biweekly
conference calls were held to ensure that the project
was progressing appropriately.
Advertisement and recruitment
Our recruitment efforts were mostly web-based
through the Centers for Disease Control (CDC)
ALS patient registry (https://www.cdc.gov/als/),
and the ALS Association and the Muscular
Dystrophy Association websites. We also adver-
tised through Facebook and Google Ads, in add-
ition to maintaining a social media presence on
Facebook®, Twitter®, and Reddit®. Some in-per-
son recruitment was completed at ALS clinics.
Figure 1. Simplified, basic concepts concerning sampling frequency and ability to accurately measure the true slope of disease
progression, assuming a linear decline over time. (A) Standard clinical trial design in which only intermittent assessments are obtained
in any given patient. There is a great deal of uncertainty in the true rate of progression (see wide 95% confidence intervals). (B)
Clinical trial design with frequency measurements. Although there continues to be noise in any individual measurement, by frequent
sampling the uncertainty in the estimation of the true slope is much smaller.
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ALS patient inclusion criteria were kept intention-
ally broad, and included a diagnosis of ALS within
five years and no known additional neurological
disorder of relevance. Healthy subject criteria
included having no history of a generalized neuro-
logical condition.
Tools for data collection
The overall architecture for data collection is sum-
marized in Figure 3. A single HIPAA-compliant
REDCap database was designed for the outcomes
data (with the exception of voice data). The
REDCap database was populated either from the
ALS AT HOME website or from apps on Android
or Apple smartphones. A new ALS AT HOME
app was also created for both iOS and Android
smartphones. A number of data collection tools
were utilized, as follows:
Hand grip dynamometer We used the Camry
Handgrip Dynamometer (Camry Scale-USA, City
Industry, California,). Data was uploaded
manually to the Internet via the ALS AT
HOME website.
Actigraph The Mi Band® (Xiaomi Corp, Beijing,
China) was used for this purpose. It has a direct
Bluetooth interface with the Mi Fit app, allowing
data to be automatically uploaded to a smart-
phone. Activity data was populated to REDCap
via application program interfaces (APIs), synchro-
nizing with the Apple Health app for iOS and
Google Fit for Android. Data automatically trans-
ferred to REDCap whenever the participant
opened the ALS AT HOME app.
Spirometer We used the AirSmart Spirometer
(Nuvoair AB, Stockholm, Sweden). Respiratory
data, including FVC and FEV1, was stored in the
Air Smart’s health cloud after measures were
obtained. For iOS users, respiratory data was
extracted with the Apple Health app via the study
app to REDCap. For Android users, a Python
code was developed and executed weekly to extract
data directly from the Air Smart database before
transferring to REDCap.
Electrical impedance myography (EIM) tool
The Skulpt Scanner (Myolex, Inc, Boston, MA)
was used for this purpose. EIM data, collected on
bilateral biceps, forearms, calves, and quadriceps,
were uploaded via Bluetooth to the Skulpt app
and transferred to a Myolex, Inc server. A Python
code was created to pull data from the Skulpt
database and transfer it to REDCap weekly.
Speech app A separate ALS AT HOME speech
app was developed specifically by Aural Analytics
(Phoenix, Arizona, USA). Patients downloaded the
app to their smartphones and spoke specific
phrases into the phone. Speech samples were then
automatically uploaded to a separate cloud-based
repository for analysis.
Questionnaire data These data included the
ALSFRS-R (5) and patient reported experience
Figure 2. Overall set-up of ALS-at-home study across the 2 sites, Barrow Neurological Institute (BNI) and Beth Israel Deaconess
Medical Center (BIDMC). BNI served as the main center for conducting the trial whereas BIDMC oversaw all the electronic-web
infrastructure development and application.
Figure 3. Diagram showing the complex interconnection
between various components of the data acquisition system.
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measures (PREMs): both surveys were created and
built in the REDCap database and appeared at the
time of patient log-in at the website on specific
days: ALSFRS-R links appeared weekly for ALS
patients only while PREM links appeared on day
7, three months, six months, and nine months
automatically for all participants. After completion,
all answers were stored in REDCap.
The participant study experience Figure 4 out-
lines the overall experience of the participant.
After learning about the study, the participant
would go to the ALS AT HOME website to
answer the prescreening questions. These ques-
tions were designed to address whether the patient
was planning to serve as a healthy control or was
an ALS patient, and to make an initial ruling on
whether the individual would be eligible for the
study. In either case, they would be asked to pro-
vide their contact information. They would then
be contacted by the study liaison at BNI, provided
more details regarding participation, and asked to
provide basic medical records (if an ALS patient)
to confirm that they had a diagnosis of ALS with
time from diagnosis of less than five years.
Records were reviewed by Dr. Shefner; subsequent
to diagnosis and disease duration confirmation,
they were invited to participate in the study.
Similarly, for healthy controls, the study would be
explained in more detail and questions answered.
If the participant was eligible, they were then asked
to participate in an informed consent webinar that
was held on a regular basis; these were performed
in such a manner that all participants were blind
to the names of other participants. The study
liaison at BNI held these webinars and questions
were answered live during the webinar. After par-
ticipating in the informed consent webinar, the
potential participants would be provided a link to
an electronic BNI institutional review board-
approved ICF that they could complete. They
would be able to keep one copy for themselves
after signing.
Once formally enrolled, the participant would
then be shipped a package containing all the prod-
ucts to be used in the data collection described
above. They would then be asked to review a ser-
ies of instructional videos created at BNI to
explain how the devices were used. After reviewing
these videos, participants completed an online test
to ensure they understood their proper use.
Participants received feedback on their perform-
ance and could keep taking the test until they
demonstrated adequate proficiency. At that point,
participants were formally invited to begin collect-
ing data using the various tools.
Data collection schedule
Participants were asked to obtain all outcome
measures daily for 90 days, then twice weekly for
an additional 180 days. The exception to this was
the ALSFRS-R, which ALS participants were
asked to fill out online weekly for the duration of
the study. Ongoing feedback would be provided to
the participants via the study liaison at BNI. All
participants had email and phone contact informa-
tion if they had questions or encountered problems
during the data collection procedures. At the 3-
month point (the conclusion of daily data collec-
tion), participation would be rewarded with an
ALS AT HOME t-shirt; at the conclusion of nine
months, participants would be sent an ALS AT
HOME hat.
Results
Enrollees/drop-outs to date
Five hundred and fifty three potentially eligible
individuals completed the eligibility questionnaire
on the ALS AT Home website over the 14-month
period of recruitment. Of these, 101 were healthy
Figure 4. Patient experience from initial prescreening to the point of data collection.
64 S. B. RUTKOVE ET AL.
subjects of whom 32 attended an informed consent
webinar, 30 signed the informed consent and
received equipment, and 25 began contributing
data. Similarly, 452 potentially eligible participants
with ALS completed the eligibility questionnaire
and were asked to submit medical records, and we
received records from 175 individuals. Of this
group, 157 individuals met the inclusion criteria
(diagnosis of ALS less than five years from date of
records receipt), and were invited to participate in
an informed consent webinar. One hundred and
eleven individuals were consented, 106 received
equipment, and 75 began contributing data.
Geographic distribution of subjects
Subjects were recruited from 41 states, with the
highest total number of participants in California,
and multiple states with only one participant. The
number of ALS and healthy participants in each
state are depicted in Figures 5(a) and 5(b).
Baseline values
Table 1 provides baseline data for the entire group
of individuals enrolled. Most notably, most ALS
patients and healthy volunteers were able to suc-
cessfully collect initial data. Reduced mean values
in most parameters were observed in the ALS
patients compared to the healthy controls,
although the range of values for both groups across
parameters was quite large.
Discussion
This is a novel study in many respects. First, par-
ticipants were enrolled, consented, and trained
online, without ever going to a study site. Thus,
we have shown that it is possible to solicit, pre-
screen, enroll, screen, and successfully begin col-
lecting data in a completely remote study. Perhaps
the overall most important finding of the study to
date is that it is feasible to institute an almost
entirely remote study with individuals collecting
data on themselves or with the help of a caregiver.
At the outset of this effort, we had concerns that
people might be suspicious of this study or simply
unwilling to enroll given their lack of human con-
nection with the study organizers, as well as there
being no therapeutic intervention. However, we
have found that having a dedicated study liaison
who is available to answer queries either by voice
phone call or email is sufficient to engage subjects
through the enrollment process to the point of ini-
tial data collection.
Another aspect that was novel included enroll-
ment entirely based on patient’s medical records
without our physically evaluating the potential par-
ticipant. This was generally not challenging,
although we inevitably lost some potential
Figure 5. Geographic distribution of healthy and ALS participants.
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participants who had trouble accessing or deliver-
ing the needed documentation. Similarly, the con-
senting webinar was easily arranged and applied
using standard Internet tools. Inasmuch as pos-
sible, these were organized so as to present the
information to as many individuals as possible at a
time; approximately one dozen webinars were pro-
vided during the course of the enrollment period.
We also had concerns that the computer and
smartphone applications might prove difficult for
participants to navigate. However, the participants
who reached the point of entering data were suffi-
ciently familiar with digital devices so as to be able
to manage the various apps and over-the-Internet
communications. Another concern we had from
the outset was that the study might be too tech-
heavy, making it excessively onerous and complex
to obtain data. However, it appears that the major-
ity of individuals are sufficiently comfortable to
collect and transmit the data.
We have also demonstrated that online recruit-
ment tools can be used successfully in this patient
population. Rather than recruiting through clinics
via face-to-face interactions, almost all of our
advertising was through the CDC ALS patient
registry (https://www.cdc.gov/als/) and foundation
websites. In addition, we used standard online
recruitment tools including Facebook and Google
paid ads. All of these were successful in bringing
people to our webpage.
There were several challenges that we encoun-
tered in the implementation and performance of
this study. First, given that many of the Internet
and device tools used in this study were propri-
etary, intermittent but frequent updates to the
various software components are needed, even
during the enrollment period. This included regu-
lar updates to smartphone operating systems, to
the specific smart phone apps, and to the firmware
embedded in any Bluetooth enabled Internet-con-
nected devices. While most of these did not inter-
fere with our ability to collect data, some required
urgent modifications of our software in order to
maintain continued error-free operation. Second,
none of the tools have been problem-free, and
even the relatively simple digital grip dynamometer
presented challenges. It can give data in pounds/
kilograms, and we need to ensure they are provid-
ing us the accurate data. Similarly the air smart
spirometer, the Mi-Band, and Skulpt Scanner have
had technical challenges. Some people were unable
to interface the device with the Internet effectively
while others simply could get the device to work
properly at first. Whether this is a fault with the
device itself or simply inexperience on the user’s
part was often unclear. Third, participants often
complained of difficulties with one more aspects of
data collection or device function. While most of
these were relatively straightforward to address,
some problems remained entirely unresolved des-
pite a dedicated effort by our study to team to
identify the problem.
Another challenge was that the online nature of
this study limited our ability to effectively under-
stand challenges to participant attrition. Unlike
most studies in which the study team develops a
close rapport with the participants, the lack of any
meaningful connection with participants meant that
when people went “radio silent” during the enroll-
ment and training process we often lacked the abil-
ity to determine the reason for the lack of contact.
Many of the challenges discussed above were
expected from the outset, although we did not
have clear expectations of which would be most
serious. In addition, a number of unexpected chal-
lenges were noted. For example, shortly after fund-
ing, two of the companies whose activity trackers
we were going to utilize could no longer supply
the tracker, either because the company went out
of business or it stopped producing the product.
Accordingly, we found ourselves needing to stock
up on products to ensure availability to partici-
pants throughout the study. Another unexpected
issue was that Nuvoair changed its policy regarding
Table 1. Baseline data.
ALS patients Healthy controls p value†
Age of enrolled subjects years
(median, range)
60 (30–80) years 51 (27–79) years 0.0197
Sex (F/M) 42/65 20/9 NA
% Completing the first set of
measurements of those
shipped equipment
71.67% 86.67% NA
ALSFRS-R median (range) 34, (9–43) points NA NA
Bilateral Grip dynamometry*
in pounds
46.7 (5.85–119.00) pounds 59.2 (5.9–115.3) pounds 0.0403
FVC (median, range) 3.20 (0.520– 6.45) Liters 3.62 (2.05–7.06) Liters 0.1801
Biceps EIM 50 kHz phase
(median, range)
10.3 (5.9–25.8) degrees 12.2 (7.2–21.5) degrees 0.554
Quadriceps EIM 50 kHz phase
(medina, range)
8.9 (4.4–19.3) degrees 9.9 (7.3–15.0) degrees 0.509
Actigraphy (median, range) 931 (4–7280) steps 4596 (377–25681) steps <0.0001
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data and required us to pay an extra fee to have
access to all the AirSmart data that was to
be collected.
The online nature of the study also led to some
unique concerns. For example, several providers
reached out to us suspicious that the study was not
legitimate and was an Internet gimmick of some
sort. These concerns were fairly easy to overcome,
but underscores perceptions about the Internet and
the solicitation of participants sight-unseen.
For convenience and simplicity, this study was
restricted to the United States with only one set of
governing laws overseeing clinical studies.
Nevertheless, it remains possible to perform such a
study across international borders. There would be
some additional challenges associated with this
beyond requiring additional approvals in different
countries. For example, shipping devices to differ-
ent countries may be problematical in certain sit-
uations, and it is conceivable that Internet
censoring in some countries could hamper recruit-
ment or other aspects of study data collection.
Regardless of the challenges associated with this
approach, we suggest that it may be possible to start
moving clinical trials out of the clinic and, inasmuch
as possible, into the home. Once this study draws to
conclusion in the coming months, we will provide a
full data set that will likely reveal additional chal-
lenges and successes to undertaking this new
approach to ALS data collection. The potential
improvements in sample size requirements, the
added convenience to participants, and the new
insights obtained into the short-term behavior of the
disease could make such an approach the preferred
method for most future ALS therapeutic trials.
Disclosure statement
Dr. Rutkove has equity in, and serves a consultant
and scientific advisor to, Myolex, Inc. a company
that designs impedance devices for clinical and
research use; he is also a member of the
company’s Board of Directors. The company also
has an option to license patented impedance
technology of which Dr. Rutkove is named as an
inventor. Drs. Berisha and Liss serve as Chief
Science Officer and Chief Clinical Officer at Aural
Analytics, Inc, a company that develops objective
measures of neurological health. Both Dr. Berisha
and Dr. Liss have equity in the company and serve
on the Board of Directors.
Funding
ALS-Finding-A Cure provided primary support for
this study. Additional support was provided via
NIH grant R44 NS070385.
References
1. Petrov D, Mansfield C, Moussy A, Hermine O. ALS
clinical trials review: 20 years of failure. Are we any closer
to registering a new treatment? Vol. 9, Frontiers in Aging
Neuroscience. 2017.
2. Abe K, Aoki M, Tsuji S, Itoyama Y, Sobue G, Togo M,
et al. Safety and efficacy of edaravone in well defined
patients with amyotrophic lateral sclerosis: a randomised,
double-blind, placebo-controlled trial. Lancet Neurol
[Internet]. 2017;[cited 2017 Jun 18]16:505–12. Available
from: http://www.ncbi.nlm.nih.gov/pubmed/28522181
3. Atassi N, Yerramilli-Rao P, Szymonifka J, Yu H, Kearney
M, Grasso D, et al. Analysis of start-up, retention, and
adherence in ALS clinical trials. Neurology. 2013;81:
1350–5.
4. Dodge HH, Zhu J, Mattek NC, Austin D, Kornfeld J,
Kaye JA. Use of high-frequency in-home monitoring data
may reduce sample sizes needed in clinical trials. PLoS
One. 2015;10:e0138095.
5. Cedarbaum JM, Stambler N, Malta E, Fuller C, Hilt D,
Thurmond B, et al. The ALSFRS-R: a revised ALS
functional rating scale that incorporates assessments of
respiratory function. BDNF ALS Study Group (Phase
III). J Neurol Sci. 1999;169:13–21.
ALS longitudinal studies 67
